Prophylaxis against ventricular arrhythmias during and after acute myocardial infarction
- Philip J Podrid, MD, FACC
Philip J Podrid, MD, FACC
- Professor of Medicine, Professor of Pharmacology and Experimental Therapeutics
- Boston University School of Medicine
- Lecturer, Harvard Medical School
- Leonard I Ganz, MD, FHRS, FACC
Leonard I Ganz, MD, FHRS, FACC
- Section Editor — Cardiac Arrhythmias
- Director of Cardiac Electrophysiology
- Heritage Valley Health System
- Section Editors
- Brian Olshansky, MD
Brian Olshansky, MD
- Section Editor — Cardiac Arrhythmias
- Adjunct Professor of Medicine
- Des Moines University
- Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
- Editor-in-Chief — Cardiovascular Medicine
- Section Editor — Coronary Heart Disease; Myopericardial Disease
- Professor of Medicine
- Mayo Clinic College of Medicine
Sudden cardiac death (SCD) in the setting of an acute myocardial infarction (MI) is most frequently the result of a ventricular tachyarrhythmia. The appearance of a sustained ventricular tachyarrhythmia following a myocardial infarction, such as ventricular tachycardia (VT) or ventricular fibrillation (VF), in the early period post-MI may be the harbinger of ongoing myocardial ischemia, the development of pro-arrhythmic myocardial scar tissue, elevated sympathetic tone or increase in circulating catecholamines, or an electrolyte disturbance such as hypokalemia. In-hospital mortality approaches 20 percent or more in patients who develop VT or VF following a myocardial infarction. As such, rapid identification and treatment of these arrhythmias can be life-saving. (See "Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction".)
Because of the marked increase in mortality associated with ventricular arrhythmias following a myocardial infarction, many researchers have focused on ways to prevent ventricular arrhythmias in the early post-MI period. This topic will focus on prophylaxis against ventricular arrhythmias following myocardial infarction (MI), primarily focusing on the appropriate use or non-use of antiarrhythmic medications. Treatment for established ventricular arrhythmias in the post-MI patient, using defibrillation with or without antiarrhythmic medications, is discussed separately. (See "Advanced cardiac life support (ACLS) in adults" and "Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction", section on 'Sustained ventricular tachycardia' and "Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction", section on 'Ventricular fibrillation' and "Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction".)
TYPES OF VENTRICULAR ARRHYTHMIAS
While many studies have evaluated the incidence of ventricular arrhythmias in the peri-infarct period, comparison of these studies is difficult due to differences in populations (percutaneous intervention therapy versus fibrinolytic therapy versus no therapy), type of infarct (ST elevation myocardial infarction (STEMI) versus non-STEMI versus both) and types of arrhythmia reported (eg, ventricular premature beats, ventricular tachycardia, ventricular fibrillation). The clinical significance of different types of ventricular ectopy following myocardial infarction also varies markedly.
Ventricular premature beats — Ventricular premature beats (VPBs), which are typically asymptomatic, are common after acute MI with a reported incidence as high as 93 percent . The early occurrence of VPBs does not predict short- or long-term mortality, but frequent and/or multiform VPBs that persist more than 48 to 72 hours after an MI may be associated with an increased long-term arrhythmic risk. Also of importance early after an acute MI are R-on-T VPBs. The pathogenesis of VPBs after MI and issues related to VPBs in patients with a prior MI are discussed separately. (See "Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction", section on 'Ventricular premature beats'.)
Non-sustained ventricular tachycardia — The significance of non-sustained ventricular tachycardia (NSVT) following myocardial infarction (MI) or acute coronary syndrome (ACS) is dependent upon the proximity of the arrhythmia to the time of the MI. In the first 24 to 48 hours after MI, NSVT is usually due to transient abnormalities of automaticity or triggered activity in the region of ischemia or infarction; in comparison, NSVT that occurs later is more often due to reentry and permanent arrhythmic substrate. However, the incidence and prognostic significance of NSVT appear lower with contemporary primary percutaneous reperfusion therapies. (See "Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction" and "Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction", section on 'NSVT on monitoring'.)
- Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19:255.
- Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2010; 122:455.
- Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009; 301:1779.
- de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation 1993; 88:915.
- Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.
- Thomsen PE, Jons C, Raatikainen P, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the cardiac arrhythmias and risk stratification after acute myocardial infarction (CARISMA) study. Circulation 2010; 121:1258.
- Volpi A, Cavalli A, Santoro L, Negri E. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. Am J Cardiol 1998; 82:265.
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).
- Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med 1992; 152:40.
- Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270:1589.
- Rydén L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308:614.
- Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622.
- American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O'Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:e78.
- Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.
- Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327:227.
- Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. N Engl J Med 1974; 291:1324.
- Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med 1985; 313:1105.
- Darby S, Cruickshank JC, Bennett MA, Pentecost BL. Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet 1972; 1:817.
- Wyman MG, Wyman RM, Cannom DS, Criley JM. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol 2004; 94:545.
- Dunn HM, McComb JM, Kinney CD, et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. Am Heart J 1985; 110:353.
- MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 1988; 260:1910.
- Sadowski ZP, Alexander JH, Skrabucha B, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999; 137:792.
- Alexander JH, Granger CB, Sadowski Z, et al. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J 1999; 137:799.
- Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16:1711.
- Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.
- Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667.
- Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.
- Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.
- Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.
- TYPES OF VENTRICULAR ARRHYTHMIAS
- Ventricular premature beats
- Non-sustained ventricular tachycardia
- Accelerated idioventricular rhythm
- Sustained ventricular tachycardia
- - Sustained monomorphic ventricular tachycardia
- - Polymorphic ventricular tachycardia
- Ventricular fibrillation
- Late arrhythmias
- Electrolyte supplementation
- - Potassium
- - Magnesium
- Beta blockers
- Antiarrhythmic drugs
- - Class Ic agents
- - Lidocaine
- - Amiodarone
- Device therapy
- SUMMARY AND RECOMMENDATIONS